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Introduction
Methylation of histone proteins constitutes a principal chro-
matin-regulatory mechanism that influences fundamental 
DNA-templated processes such as gene transcription.1 Genetic 
abnormalities affecting the enzymes responsible for catalyz-
ing the formation of histone methyl marks have been shown to 
play a significant role in the development of cancer and other 
diseases.1,2 For example, in multiple myeloma, a recurrent chro-
mosomal translocation leads to overexpression of the lysine 
methyltransferase (KMT) MMSET (also named NSD2 and 
WHSC1), which dimethylates H3K36 to drive oncogenic pro-
gramming.3 Neomorphic mutations of the KMT EZH2 have 
been found in patients suffering from diffuse large B-cell lym-
phoma and follicular lymphoma, implicating increased H3K27 
trimethylation in the etiology of these cancers.4 These findings 
exemplify the potential clinical consequences of aberrant histone 
methylation, and suggest that increased understanding of his-
tone methyltransferases will reveal important targets for oncol-
ogy drug discovery.
Smyd3 (SET and MYND domain containing protein 3) is a 
KMT that is highly overexpressed in several cancers including 
liver, breast and rectal carcinomas.5,6 Recent studies have begun to 
elucidate the oncogenic roles of Smyd3 including stimulation of 
proliferation, adhesion and migration.7 While these studies high-
light the involvement of Smyd3 in cancer and suggest an oppor-
tunity for chemotherapeutic intervention, a clear physiological 
function for the catalytic activity of Smyd3 remains obscure. On 
histones, Smyd3 has been reported to have conflicting activities, 
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methylating either lysine 4 of histone H3 (H3K4) or lysine 20 of 
histone H4 (H4K20).5,8 We therefore took an unbiased substrate 
specificity screening strategy to identify the preferred histone 
residue methylated by Smyd3.
Results and Discussion
The methylation activity of recombinant full-length Smyd3 
was screened against a library of 327 modified and unmodi-
fied histone peptides (see Table S1 for peptide content). The 
most highly methylated peptides were derived from histone H4 
residues 1–21 (Fig. 1A; Table S1). None of the H3 peptides 
in the panel showed any activity as substrates including pep-
tides that are unmethylated, mono- or di-methylated at H3K4   
(Fig. 1A). Moreover, Smyd3 methylated histone recombinant 
H4, but three different Smyd3 catalytic mutants (Smyd3F183A, 
Smyd3N205A and Smyd3Y239A) failed to do so (Fig. 1B;   
Fig. S1). Additionally, Smyd3 demonstrated 10-fold higher activ-
ity with recombinant histone H4 as compared to histone H3 
(Fig. 1C). When reconstituted nucleosomes were used as sub-
strates, Smyd3 methylated H4, like the positive control SET8/
PR-Set7,9,10 but not the other core histones (Fig. 1D).
To determine which H4 lysine residue is modified by Smyd3, 
a recombinant library was generated in which only a single lysine 
residue on the H4 tail is present and available to undergo meth-
ylation. In this assay, H4K20 did not serve as a substrate, but 
methylation was observed primarily on K5, with very low activity 
also observed on K8 and K12 (Fig. 2A). Liquid chromatography 
coupled with tandem mass spectrometry (LC-MS/MS) analysis © 2012 Landes Bioscience.
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(Table S2 and Fig. S3). Furthermore, global levels of H3K4 and 
H4K20 methylation in HeLa cells did not increase upon Smyd3 
overexpression (Fig. S4).
Consistent with previous reports, Smyd3 depletion attenu-
ated proliferation of human carcinoma cell lines (Fig. S5).5 In 
addition, human breast carcinoma MCF7 cells and hepatoma 
Hep3B cells both lost the ability to form colonies in an anchor-
age-independent environment upon stable depletion of Smyd3 
using shRNA directed to the 3' UTR of Smyd3 (Fig. 3A and B).   
Colony formation was restored in Smyd3 depleted cells by 
complementation with wild-type Smyd3 (lacking the 3' UTR 
and therefore RNAi-resistant) (Fig. 3A and B), whereas com-
plementation with catalytically dead Smyd3 (Smyd3N205A 
(Fig. 3A) and Smyd3F183A (Fig. 3B) failed to reconstitute this 
activity. Moreover, global levels of H3K4me3 and H4K20me3 
were unchanged upon Smyd3 knockdown in MCF7 cells   
(Fig. S6). Therefore, we conclude that while anchorage inde-
pendent growth of MCF7 cells requires Smyd3 activity, main-
tenance of the global levels of H3K4me3 and H4K20me3 does 
not. Thus, Smyd3 is required for H4K5 methylation in cells and 
of recombinant H4 methylated by Smyd3 identified H4K5me1 
as the most abundant species, and also detected H4K5me2, 
H4K5me3 and H4K12me1 species, but no other methylation 
sites were detected including H4K20 (Fig. 2B). Thus, we con-
clude that in vitro Smyd3 primarily methylates histone H4 at 
lysine 5.
Smyd3 is detected in both the cytoplasm and nucleus 
(Fig. S2). Thus, while methylation of H4K5 in human cells 
has not been described to date, Smyd3 nuclear localization sug-
gests that it could generate this mark in vivo. In this context, 
an unbiased MS/MS based approach was used to quantify the 
methylation states of all lysine residues present on histones H3 
and H4 in two model cells systems, Smyd3 depleted HeLa cells 
and Smyd3 knockout mouse embryonic fibroblasts (MEFs) 
(Fig. 2C and D). H4K5me1 was detected in both cell types and 
the levels of this mark were significantly reduced upon Smyd3 
knockdown or knockout (Fig. 2D; Table S2). Notably, in this 
analysis, no significant changes were observed in the methyla-
tion states of any of the other lysine residues including the pre-
viously implicated Smyd3 substrate sites of H3K4 and H4K20   
Figure 1. SMYD3 selectively methylates H4 in vitro. (A) Heat map summarizing results from a library of 327 histone peptides tested as Smyd3 methyla-
tion substrates. peptides were derived from histones H2a, H2b, H3 and H4 and possessed various combinations of modifications (see Table S1).  
(B) Methylation assays using the indicated recombinant Smyd3 proteins on free recombinant histone H4. Autoradiograph and Coomassie stained gels 
(loading control) are shown. (C) Quantitative evaluation of Smyd3 methylation using recombinant histones H3 and H4. (D) Methylation assays as in  
(B) using reconstituted nucleosomes. SEt8 is known to methylate nucleosomal H4.9© 2012 Landes Bioscience.
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Figure 2. Smyd3 methylates H4K5 in vitro and in vivo. (A) Methylation assay on H4 peptide residues 1–36, and H4 derived peptides with all lysines 
mutated to arginine (ΔKall) or single lysine maintained and all other lysines mutated to arginine as indicated (ΔK5* refers to a similar H4 peptide with 
all lysines mutated except K5). (B) LC-MS/MS analysis of Smyd3 methylated recombinant H4. (C) Western blot analysis with the indicated antibodies of 
whole cell extracts (left) from HeLa cells expressing the indicated sirNAs and (right) wild-type and Smyd3-/- MEfs. (D) Quantitative mass spectrometry 
of the relative amounts of the indicated histone methylation marks in HeLa cells for Smyd3 positive/Smyd3 depleted cells (gray bars) and in wild type 
MEfs/SMYD3-/- MEfs (black bars).
Figure 3. Smyd3 catalytic activity is required for anchorage-independent growth of cancer cells. (A and B) Complementation of Smyd3-depleted 
cells with wild-type Smyd3 but not catalytically dead Smyd3 restores anchorage-independent growth. (A) Left: quantification of colony formation in 
methylcellulose after 10 d of Hep3b cells treated with either control shrNA or 3'Utr shSmyd3 reconstituted with Gfp, Smyd3-Wt or catalytically inac-
tive Smyd3N205A. right: western blot analysis of Hep3B whole cell extracts. (B) Left: quantification of colony formation in soft agar after 14 d of MCf7 
cells treated with either control shrNA or 3'Utr shSmyd3 reconstituted with flag-control vector, flag-Smyd3-Wt or catalytically inactive flag-Smyd-
3f183A. right: Western blot analysis of MCf7 whole cell extracts. Bar graphs indicate the number of colonies per field. Error bars indicate the standard 
deviation (SD) from three independent experiments. the p values indicate the statistical significance as determined by t-test between the different 
conditions marked with * or **.© 2012 Landes Bioscience.
Do not distribute.
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its enzymatic activity is important for maintaining transformed 
cell phenotypes associated with high Smyd3 expression.
Here we report a novel site of histone modification, H4K5 
methylation, which is catalyzed by the putative oncoprotein 
Smyd3. Future work aimed at understanding the molecular 
functions of H4K5 methylation in Smyd3-mediated oncogenic 
phenotypes should provide new insight into how chromatin 
methylation impacts human disease. Taken together, our results 
indicate that the likely physiologic chromatin target of Smyd3 is 
H4K5 methylation, and suggest that the catalytic methyltrans-
ferase activity of Smyd3 is an important target for anti-cancer 
drug discovery.
Materials and Methods
Materials and methods are detailed in the Supplemental 
Materials.
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